Working... Menu

Infective Endocarditis After TAVR (INTENSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03768180
Recruitment Status : Active, not recruiting
First Posted : December 7, 2018
Last Update Posted : March 29, 2019
Information provided by (Responsible Party):
Region Skane

Brief Summary:
This study aims at studying the frequency of infective endocarditis after transcatheter aortic valve replacement/implantation

Condition or disease
Infective Endocarditis of Aortic Valve

Detailed Description:
Since the start of transcatheter aortic valve implnatations/replacements (TAVR/TAVI) implantations in Sweden in 2008 all procedures have been added to a national database, which now contains 4500+ procedures. At the same time, all admissions to the hospital is also recorded with diagnosis in a separate database. We intend to make a nation-wide complete follow up of all TAVR/TAVI patients in swede that has received the diagnosis of infective endocarditis after the implantation. In addition data will also be collected from the national endocarditis database for detailed information of the cases.

Layout table for study information
Study Type : Observational
Actual Enrollment : 4600 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: INfecTive ENdocarditis After Transcatheter Aortic Valve Replacement (TAVR) a National SwEdish Study (INTENSE)
Actual Study Start Date : January 1, 2018
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : October 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endocarditis

Patient with infective endocarditis
All patients diagnosed with infective endocarditis after TAVR

Primary Outcome Measures :
  1. Infective Endocarditis [ Time Frame: 5 year ]
    Patients that have suffered an infective endocarditis will be described, where survival is one important variable

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All patients that has under TAVR/TAVI in Sweden between 2008 and 2018

Inclusion Criteria:

All patients that has under TAVR/TAVI in Sweden between 2008 and 2018

Exclusion Criteria:

Patients unable to follow up due to emigration or missing social security number

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03768180

Layout table for location information
Skane University Hospital
Lund, Sweden, 22185
Sponsors and Collaborators
Region Skane

Layout table for additonal information
Responsible Party: Region Skane Identifier: NCT03768180     History of Changes
Other Study ID Numbers: IETAVR
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: March 29, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Endocarditis, Bacterial
Heart Diseases
Cardiovascular Diseases
Bacterial Infections
Cardiovascular Infections